Citizen Watches Leather Straps
Public Citizen Names Two Groups For Whom Fosamax Has No Benefit of Therapy
Because millions of Americans are afflicted with osteoporosis, bone-strengthening drug Fosamax has been considered one of the bestselling drugs in the United States and North America. However, the use of this bisphosphonate entails serious adverse effects, including osteonecrosis of the jaw. But before anything else, let’s take deeper look on this severe dental condition called osteonecrosis of the jaw.
In the recent past, the food and drug Administration (FDA) had discussed about health care providers not carefully prescribing biphosphonates to their patients. Consumer advocacy group Public Citizen named two groups who are not gaining therapeutic benefits from Fosamax therapy. These people may be needlessly risking themselves to this jaw bone condition.
Osteonecrosis of the jaw, commonly referred to as ONJ or “dead jaw,” is a disease characterized by an exposure of the jawbone. This bone tissue does not receive enough blood supply, which eventually leads to the its death or necrosis. Scientists have coined the terms “Bis-phossy Jaw” and BON for ONJ in relation to the use of bisphosphonates like Fosamax.
During the first stage of ONJ, patient seems asymptomatic until the later stages when one could experience pain, swelling and redness usually associated with gum infections. The hallmark sign of ONJ is the exposure of bone tissue which lasts for more than 2 months. Furthermore, a dental procedure would often exacerbate or worsen the condition.
In most cases, ONJ is treated non-surgically with antimicrobial rinses, systemic antibiotics, systemic or topical antifungal medications and pain reliever. When advanced stages are reached, surgical debridement or resection, together with nonsurgical interventions, might be performed. It if best for anyone who have the symptoms to inform his/her dental specialist know if he/she is on bisphosphonate therapy before any dental procedure – even minor surgery – is performed.
In July 2005, Merck changed the label of Fosamax regarding ONJ risk as ordered by FDA. Yet, some Fosamax patients, who are using the drug for a long time, believed that Merck did not properly warned its patients, causing them to deal with the side effects and other drug backlash. This moved affected men and women to file Fosamax lawsuit against the pharmaceutical company.
Citizen Watch: Citizen Men's Black IP Chronograph Leather Strap AT0875-09E - video
We appreciate you taking the time to visit our website
and hope that we were able to help you in your search for the information that you are looking for.
We do realize that with so many articles written, it is possible
and even likely that you will find mistakes along the way.
We would greatly appreciate you using the "contact us" page to let us know if you come across any mistakes
in our articles or if you simply have some ideas for articles that you would like to see in the future.
Thanks again for taking the time to visit,
we hope you have enjoyed you stay and hope that you will visit us again someday very soon.
